{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.7","upperLimit":"23.5","value":"9.4"},{"comment":"Upper limit of 95% CI was not estimable as there were less number of participants with an event.","groupId":"OG001","lowerLimit":"1.7","upperLimit":"NA","value":"7.4"},{"comment":"Upper limit of 95% CI was not estimable as there were less number of participants with an event.","groupId":"OG002","lowerLimit":"5.1","upperLimit":"NA","value":"16.2"},{"groupId":"OG003","lowerLimit":"1.2","upperLimit":"22.5","value":"6.1"},{"groupId":"OG004","lowerLimit":"3.4","upperLimit":"25.2","value":"8.5"},{"comment":"Upper limit of 95% CI was not estimable as there were less number of participants with an event.","groupId":"OG005","lowerLimit":"1.8","upperLimit":"NA","value":"6.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"11"}],"units":"Participants"}],"description":"OS was defined as the time (in months) from the date of first dose of study drug to the date of death due to any cause or data censoring date, whichever occurred first. Participants last known to be alive were censored at the date of last contact. OS was analyzed by Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"During Phase 1b participants received utomilumab 20 mg IV Q4W along with PF-04518600 0.1 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG000","title":"Combination D Phase 1b: Utomilumab 20 mg + PF-04518600 0.1 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 50 mg IV Q4W along with PF-04518600 0.1 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG001","title":"Combination D Phase 1b: Utomilumab 50 mg + PF-04518600 0.1 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 20 mg IV Q4W along with PF-04518600 0.3 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG002","title":"Combination D Phase 1b: Utomilumab 20 mg + PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 50 mg IV Q4W along with PF-04518600 0.3 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG003","title":"Combination D Phase 1b: Utomilumab 50 mg + PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 20 mg IV Q4W along with PF-04518600 1.0 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG004","title":"Combination D Phase 1b: Utomilumab 20 mg + PF-04518600 1.0 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 50 mg IV Q4W along with PF-04518600 1.0 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG005","title":"Combination D Phase 1b: Utomilumab 50 mg + PF-04518600 1.0 mg/kg + Avelumab"}],"paramType":"MEDIAN","populationDescription":"Full analysis set included all enrolled participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug to date of death from any cause or data censoring date, whichever occurred first (maximum up to 7.3 years)","title":"OS for Combination D","type":"SECONDARY","unitOfMeasure":"Months"}